IS8503A - Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar - Google Patents
Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillarInfo
- Publication number
- IS8503A IS8503A IS8503A IS8503A IS8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A
- Authority
- IS
- Iceland
- Prior art keywords
- cannabinonide
- azate
- receptor antagonists
- formula
- cyclic heterocycles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53145103P | 2003-12-19 | 2003-12-19 | |
PCT/US2004/042878 WO2005063762A1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
US11/016,198 US7816357B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IS8503A true IS8503A (is) | 2006-06-08 |
Family
ID=34742367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8503A IS8503A (is) | 2003-12-19 | 2006-06-08 | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar |
Country Status (21)
Country | Link |
---|---|
US (1) | US7816357B2 (no) |
EP (1) | EP1697371B1 (no) |
JP (1) | JP2007514770A (no) |
KR (1) | KR20060103265A (no) |
AT (1) | ATE360631T1 (no) |
AU (1) | AU2004309368A1 (no) |
BR (1) | BRPI0417820A (no) |
CA (1) | CA2550375A1 (no) |
CY (1) | CY1106679T1 (no) |
DE (1) | DE602004006166T2 (no) |
DK (1) | DK1697371T3 (no) |
ES (1) | ES2284081T3 (no) |
HK (1) | HK1095138A1 (no) |
HR (1) | HRP20070267T3 (no) |
IL (1) | IL176110A0 (no) |
IS (1) | IS8503A (no) |
NO (1) | NO20062691L (no) |
PL (1) | PL1697371T3 (no) |
PT (1) | PT1697371E (no) |
RU (1) | RU2006126123A (no) |
WO (1) | WO2005063762A1 (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1697371T3 (da) | 2003-12-19 | 2007-09-17 | Bristol Myers Squibb Co | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer |
US20060069080A1 (en) * | 2004-09-29 | 2006-03-30 | Veltri Enrico P | Combinations of substituted azetidinones and CB1 antagonists |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
EP2127676A3 (en) * | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related disorders |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2007066601A1 (ja) | 2005-12-07 | 2007-06-14 | Sumitomo Chemical Company, Limited | ピリダジン化合物及びその用途 |
EP1958948B1 (en) | 2005-12-07 | 2011-10-05 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
WO2007096489A1 (fr) * | 2006-02-17 | 2007-08-30 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
AU2007222069A1 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
WO2008066845A2 (en) * | 2006-11-28 | 2008-06-05 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with norfluoxetine |
US8030306B2 (en) | 2006-12-14 | 2011-10-04 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
FR2910001B1 (fr) * | 2006-12-18 | 2009-03-20 | Sod Conseils Rech Applic | Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament |
AR064962A1 (es) * | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
JP2008222603A (ja) * | 2007-03-09 | 2008-09-25 | Institute Of Physical & Chemical Research | 神経変性疾患の予防・治療剤 |
DE102008000872A1 (de) | 2007-04-11 | 2008-11-13 | Basf Se | Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel |
AU2008240158B2 (en) * | 2007-04-11 | 2014-07-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
ES2439255T3 (es) * | 2007-06-21 | 2014-01-22 | Cara Therapeutics, Inc. | Imidazoheterociclos sustituidos |
US20090036426A1 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EA201070609A1 (ru) * | 2007-11-14 | 2010-12-30 | Амилин Фармасьютикалз, Инк. | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств |
WO2010079241A1 (es) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012142388A2 (en) * | 2011-04-15 | 2012-10-18 | New York University | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
EP2978859B1 (en) | 2013-03-27 | 2018-06-27 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
RS57533B1 (sr) * | 2014-01-29 | 2018-10-31 | Ucb Biopharma Sprl | Heteroaril amidi kao inhibitori proteinske agregacije |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994898A (en) * | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
IT1164198B (it) | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
JPS61106576A (ja) | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−3−オン誘導体及び製造方法 |
NZ333768A (en) | 1996-07-25 | 2000-09-29 | Merck Sharp & Dohme | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
CA2346659A1 (en) * | 1998-10-06 | 2000-04-13 | Michiyo Gyoten | Condensed pyridazine compounds, their production and use |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
AU2003205926A1 (en) * | 2002-02-07 | 2003-09-02 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
CA2478389A1 (en) * | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7351826B2 (en) | 2003-02-19 | 2008-04-01 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
DK1697371T3 (da) | 2003-12-19 | 2007-09-17 | Bristol Myers Squibb Co | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer |
TW200528455A (en) | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
-
2004
- 2004-12-17 DK DK04815007T patent/DK1697371T3/da active
- 2004-12-17 DE DE602004006166T patent/DE602004006166T2/de not_active Expired - Fee Related
- 2004-12-17 AU AU2004309368A patent/AU2004309368A1/en not_active Abandoned
- 2004-12-17 KR KR1020067011999A patent/KR20060103265A/ko not_active Application Discontinuation
- 2004-12-17 US US11/016,198 patent/US7816357B2/en active Active
- 2004-12-17 PT PT04815007T patent/PT1697371E/pt unknown
- 2004-12-17 RU RU2006126123/04A patent/RU2006126123A/ru not_active Application Discontinuation
- 2004-12-17 EP EP04815007A patent/EP1697371B1/en active Active
- 2004-12-17 ES ES04815007T patent/ES2284081T3/es active Active
- 2004-12-17 AT AT04815007T patent/ATE360631T1/de not_active IP Right Cessation
- 2004-12-17 CA CA002550375A patent/CA2550375A1/en not_active Abandoned
- 2004-12-17 WO PCT/US2004/042878 patent/WO2005063762A1/en active Application Filing
- 2004-12-17 JP JP2006545567A patent/JP2007514770A/ja active Pending
- 2004-12-17 BR BRPI0417820-3A patent/BRPI0417820A/pt not_active IP Right Cessation
- 2004-12-17 PL PL04815007T patent/PL1697371T3/pl unknown
-
2006
- 2006-06-04 IL IL176110A patent/IL176110A0/en unknown
- 2006-06-08 IS IS8503A patent/IS8503A/xx unknown
- 2006-06-12 NO NO20062691A patent/NO20062691L/no not_active Application Discontinuation
-
2007
- 2007-02-16 HK HK07101918A patent/HK1095138A1/xx not_active IP Right Cessation
- 2007-06-08 HR HR20070267T patent/HRP20070267T3/xx unknown
- 2007-06-26 CY CY20071100845T patent/CY1106679T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1697371B1 (en) | 2007-04-25 |
PL1697371T3 (pl) | 2007-09-28 |
IL176110A0 (en) | 2006-10-05 |
NO20062691L (no) | 2006-09-14 |
JP2007514770A (ja) | 2007-06-07 |
US7816357B2 (en) | 2010-10-19 |
DK1697371T3 (da) | 2007-09-17 |
PT1697371E (pt) | 2007-08-03 |
EP1697371A1 (en) | 2006-09-06 |
RU2006126123A (ru) | 2008-01-27 |
DE602004006166D1 (de) | 2007-06-06 |
HRP20070267T3 (en) | 2007-08-31 |
WO2005063762A1 (en) | 2005-07-14 |
US20050171110A1 (en) | 2005-08-04 |
BRPI0417820A (pt) | 2007-03-27 |
KR20060103265A (ko) | 2006-09-28 |
DE602004006166T2 (de) | 2008-01-10 |
CY1106679T1 (el) | 2012-05-23 |
ATE360631T1 (de) | 2007-05-15 |
ES2284081T3 (es) | 2007-11-01 |
CA2550375A1 (en) | 2005-07-14 |
HK1095138A1 (en) | 2007-04-27 |
AU2004309368A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
SE0401342D0 (sv) | Therapeutic compounds | |
TW200716628A (en) | Novel compounds | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
GB0413087D0 (en) | Therapeutic compounds | |
ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
WO2006076569A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators | |
WO2006076598A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators | |
SE0402763D0 (sv) | Nitro indazole derivatives | |
SE0401343D0 (sv) | Therapeutic compounds: Pyridine N oxide as scaffold | |
TW200626582A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
TW200626583A (en) | Novel compounds |